Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a cancer with dismal prognosis due to resistance to most current therapies. Although immunotherapy has improved the treatment of many solid cancers, pancreatic cancer remains resistant to immunotherapy due to immunosuppressive tumor microenvironmen...

Descripció completa

Dades bibliogràfiques

Autors principals:	Santeri A. Pakola, Nea Ojala, Tatiana V. Kudling, James H. A. Clubb, Elise Jirovec, Mirte van der Heijden, Victor Arias, Lyna Haybout, Saru Basnet, Susanna Grönberg-Vähä-Koskela, Dafne C. A. Quixabeira, Joao M. Santos, Victor Cervera-Carrascon, Otto Hemminki, Anna Kanerva, Harri Mustonen, Pauli Puolakkainen, Hanna Seppänen, Akseli Hemminki
Format:	Artigo
Idioma:	Inglês
Publicat:	Springer 2025-06-01
Col·lecció:	Cancer Immunology, Immunotherapy
Matèries:	Oncolytic virus Adenovirus, Pancreatic cancer Immunotherapy PD-L1 Checkpoint inhibitor
Accés en línia:	https://doi.org/10.1007/s00262-025-04072-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!